MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$42,106K
EPS
-$526.11
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
Research and development
39,802 16,043* 35,052
General and administrative
6,377 -17,767* 14,129
Total operating expenses
46,179 -1,724 49,181
Gain from operations
-46,179 1,724* -49,181
Interest income
3,944 1,011* 3,444
Income from transition services agreements
223 -1,838* 1,010
Change in fair value of participation right liability
0 725* 0
Other income (expense)
-94 55* -30
Total other income, net
4,073 -1,497* 4,424
Net gain
-42,106 227 -44,757
Basic EPS
-526.11 0.012 -1.03
Diluted EPS
-526.11 0.012 -1.03
Basic Average Shares
80,032 18,798,465 43,491,085
Diluted Average Shares
80,032 18,798,465 43,491,085
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Interest income$3,944K Income from transitionservices agreements$223K Net gain-$42,106K Total other income,net$4,073K Other income(expense)-$94K Gain from operations-$46,179K Total operatingexpenses$46,179K Research and development$39,802K General andadministrative$6,377K

BridgeBio Oncology Therapeutics, Inc. (BBOT)

BridgeBio Oncology Therapeutics, Inc. (BBOT)